How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,364 results for

Cushing Response

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01984268 Recruitment Status : Unknown Verified August 2016 by Richard C. Chou, Dartmouth-Hitchcock Medical

2013 Clinical Trials

162. Neuroendocrine and Immune Response to Stress in Schizophrenia

Neuroendocrine and Immune Response to Stress in Schizophrenia Neuroendocrine and Immune Response to Stress in Schizophrenia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Neuroendocrine and Immune Response (...) to Stress in Schizophrenia (TSST) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01975584 Recruitment Status : Completed First Posted : November 4, 2013 Last Update Posted : July 13, 2018 Sponsor: University of Maryland Information provided by (Responsible Party): Deanna Kelly, University of Maryland

2013 Clinical Trials

163. Cushing's syndrome Full Text available with Trip Pro

such as in the and around the neck, as well as in the axilla. Untreated Cushing's syndrome can lead to and increased . Cortisol can also exhibit activity in high concentrations, worsening the hypertension and leading to (common in ectopic ACTH secretion) and (increased Na+ ions concentration in plasma). Furthermore, excessive cortisol may lead to disturbances, opportunistic infections, and impaired wound healing related to cortisol's suppression of the immune and inflammatory responses. is also an issue in Cushing's (...) of glucocorticoid medication. Cushing's syndrome results from some derangement of the body's own system of secreting cortisol. Normally, is released from the when necessary to stimulate the release of cortisol from the . In pituitary Cushing's, a benign pituitary adenoma secretes ACTH. This is also known as Cushing's disease and is responsible for 70% of endogenous Cushing's syndrome. In adrenal Cushing's, excess cortisol is produced by adrenal gland tumors, hyperplastic adrenal glands, or adrenal glands

2012 Wikipedia

164. Cushing reflex

Cushing reflex Cushing reflex - Wikipedia Cushing reflex From Wikipedia, the free encyclopedia Cushing reflex (also referred to as the vasopressor response , the Cushing effect , the Cushing reaction , the Cushing phenomenon , the Cushing response , or Cushing's Law ) is a physiological nervous system response to increased (ICP) that results in of increased blood pressure, irregular breathing, and . It is usually seen in the terminal stages of acute and may indicate imminent . It can also (...) be indicative of insufficient to the brain ( ) as well as compression of . In response to rising intracranial pressure (ICP), respiratory cycles change in regularity and rate. Different patterns indicate a different location of the brain where the injury occurred. The increase in is exhibited as an increase in rate rather than depth of ventilation, so the Cushing reflex is often associated with slow, irregular breathing. As a result of the now defective regulation of heart rate and blood pressure

2012 Wikipedia

165. Cortisol and Nutritional Sympathetic Responsiveness

Cortisol and Nutritional Sympathetic Responsiveness Cortisol and Nutritional Sympathetic Responsiveness - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Cortisol and Nutritional Sympathetic Responsiveness (...) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01620684 Recruitment Status : Unknown Verified September 2014 by Nora E. Straznicky, Baker Heart Research Institute. Recruitment status was: Recruiting First Posted : June 15, 2012 Last Update Posted : September 9, 2014 Sponsor: Baker Heart Research

2012 Clinical Trials

166. Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression

Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Repeated (...) Partial Sleep Deprivation to Augment SSRI Response in Depression The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01545843 Recruitment Status : Completed First Posted : March 7, 2012 Results First Posted : January 30, 2015 Last Update Posted : December 8, 2017 Sponsor: University of Michigan Information

2012 Clinical Trials

167. ALTERED RESPONSES OF NEUROSPORA CRASSA TO INHIBITING CONCENTRATIONS OF INDOLE Full Text available with Trip Pro

ALTERED RESPONSES OF NEUROSPORA CRASSA TO INHIBITING CONCENTRATIONS OF INDOLE 16561804 2006 05 25 2018 12 01 0021-9193 58 4 1949 Oct Journal of bacteriology J. Bacteriol. ALTERED RESPONSES OF NEUROSPORA CRASSA TO INHIBITING CONCENTRATIONS OF INDOLE. 433-42 Cushing J E JE University of California, Santa Barbara College, Department of Biology, Santa Barbara, California. Schwartz M M Bennett R R eng Journal Article United States J Bacteriol 2985120R 0021-9193 0 Indoles 8724FJW4M5 indole OM Indoles

1949 Journal of bacteriology

168. V. The Counteractive Effect of Tribromethanol (Avertin) on the Stimulatory Response to Pituitrin Injected in the Ventricle Full Text available with Trip Pro

V. The Counteractive Effect of Tribromethanol (Avertin) on the Stimulatory Response to Pituitrin Injected in the Ventricle 16577355 2006 06 01 2008 11 20 0027-8424 17 5 1931 May Proceedings of the National Academy of Sciences of the United States of America Proc. Natl. Acad. Sci. U.S.A. V. The Counteractive Effect of Tribromethanol (Avertin) on the Stimulatory Response to Pituitrin Injected in the Ventricle. 248-53 Cushing H H Harvard Medical School and Peter Bent Brigham Hospital. eng Journal

1931 Proceedings of the National Academy of Sciences of the United States of America

169. II. The Similarity in the Response to Posterior Lobe Extract (Pituitrin) and to Pilocarpine When Injected into the Cerebral Ventricles Full Text available with Trip Pro

II. The Similarity in the Response to Posterior Lobe Extract (Pituitrin) and to Pilocarpine When Injected into the Cerebral Ventricles 16577341 2006 06 01 2008 11 20 0027-8424 17 4 1931 Apr Proceedings of the National Academy of Sciences of the United States of America Proc. Natl. Acad. Sci. U.S.A. II. The Similarity in the Response to Posterior Lobe Extract (Pituitrin) and to Pilocarpine When Injected into the Cerebral Ventricles. 171-7 Cushing H H Peter Bent Brigham Hospital and Harvard

1931 Proceedings of the National Academy of Sciences of the United States of America

170. Response to stress. Full Text available with Trip Pro

Response to stress. 4319949 1970 12 21 2018 11 30 0007-1447 4 5728 1970 Oct 17 British medical journal Br Med J Response to stress. 176 Besser G M GM eng Journal Article England Br Med J 0372673 0007-1447 0 Insulin 9002-60-2 Adrenocorticotropic Hormone AIM IM Adrenocorticotropic Hormone metabolism Cushing Syndrome etiology metabolism Humans Hypoglycemia chemically induced Insulin Stress, Physiological metabolism 1970 10 17 1970 10 17 0 1 1970 10 17 0 0 ppublish 4319949 PMC1819921 Lancet. 1965

1970 British medical journal

171. Acute metabolic response to human growth hormone in different types of dwarfism. Full Text available with Trip Pro

Acute metabolic response to human growth hormone in different types of dwarfism. 5339170 1967 09 03 2018 11 13 0007-1447 3 5559 1967 Jul 22 British medical journal Br Med J Acute metabolic response to human growth hormone in different types of dwarfism. 196-9 Melvin K E KE Wright A D AD Hartog M M Antcliff A C AC Copestake A M AM Fraser T R TR eng Clinical Trial Journal Article England Br Med J 0372673 0007-1447 0 Insulin 9002-72-6 Growth Hormone N762921K75 Nitrogen SY7Q814VUP Calcium (...) V27W9254FZ Cortisone AIM IM Adolescent Adult Aged Arthritis, Juvenile metabolism Asthma metabolism Blood Urea Nitrogen Body Weight Bone Development drug effects Calcium urine Carcinoma metabolism Child Clinical Trials as Topic Cortisone adverse effects Cushing Syndrome metabolism Dwarfism drug therapy metabolism Dwarfism, Pituitary metabolism Female Growth Hormone blood therapeutic use Humans Hypoglycemia metabolism Insulin Male Middle Aged Nitrogen urine Osteoporosis metabolism Turner Syndrome

1967 British medical journal

172. COVID-19 and Patients With Cancer

regimen to reduce hospital admissions hematopoietic stem cell transplantation (HSCT) autologous HSCT (AHSCT) not curative for myeloma and results in months of immune suppression consider deferring AHSCT except for patients with high-risk disease (such as genetically defined high-risk, clinically aggressive disease, or extramedullary disease) ensure full cycles of treatment given to increase disease response in anticipation of AHSCT when appropriate allogeneic HSCT should be deferred given high risk (...) neoadjuvant therapy in large T1 tumors or as per multidisciplinary board recommendations after neoadjuvant chemotherapy for ER positive invasive breast cancer if patient had partial or complete clinical response, consider converting to endocrine therapy to delay surgery vs. offering surgery in 4-8 weeks; reassess patient by telemedicine every 2-4 weeks to screen for progression if patient also has HER2 positive disease, consider converting to endocrine therapy in addition to HER2 targeted therapy to delay

2020 DynaMed Plus

173. Management of osteoporosis and the prevention of fragility fractures

for an individual case and are subject to change as scientific knowledge and technology advance and patterns of care evolve. Adherence to guideline recommendations will not ensure a successful outcome in every case, nor should they be construed as including all proper methods of care or excluding other acceptable methods of care aimed at the same results. The ultimate judgement must be made by the appropriate healthcare professional(s) responsible for clinical decisions regarding a particular clinical procedure (...) (and probably increases) the prescribers’ professional responsibility and potential liability.” 124 Management of osteoporosis and the prevention of fragility fractures The General Medical Council (GMC) recommends that when prescribing a medicine ‘off label’, doctors should: • be satisfied that there is no suitably licensed medicine that will meet the patient’s need. • be satisfied that there is sufficient evidence or experience of using the medicine to show its safety and efficacy • take responsibility

2020 SIGN

174. Auditory Brainstem Implantation for Adults With Neurofibromatosis 2 or Severe Inner Ear Abnormalities

abnormalities (i.e., nontumour indications) who are not candidates for cochlear implantation. It also evaluated the budget impact of publicly funding auditory brainstem implantation and the experiences, preferences, and values of adults with neurofibromatosis 2 or severe inner ear abnormalities. BACKGROUND Health Condition, Clinical Need, and Target Population Neurofibromatosis 2 Neurofibromatosis 2 (NF2) is a genetic disorder that affects chromosome 22, which encodes the gene responsible for the production (...) -like part of the brain that connects the two hemispheres to the spinal cord. An ABI is designed with a flat electrode paddle connected to a receiver-stimulator that is surgically placed within the lateral recess between the brainstem and the cerebellum. During surgery, electrical impulses are used to stimulate the auditory pathway, while the brain’s responses are recorded to verify the correct placement over the cochlear nucleus, where the processing of acoustic information begins. The three

2020 Health Quality Ontario

175. Implantable Devices for Single-Sided Deafness and Conductive or Mixed Hearing Loss

Armstrong (The Ottawa Hospital), Rex Banks (Canadian Hearing Society), Paul Bradley (MedTech Consulting), Joseph Chen (Sunnybrook Health Sciences Centre), Sharon Cushing (Hospital for Sick Children), Karen Gordon (Hospital for Sick Children), Gordon Guyatt (McMaster University), Vincent Lin (Sunnybrook Health Sciences Centre), Muhammad Mamdani (St. Michael's Hospital), Vicky Papaioannou (Hospital for Sick Children), Blake Papsin (Hospital for Sick Children), and David Schramm (The Ottawa Hospital). We (...) publications in the clinical evidence review. For adults and children with single- sided deafness, cochlear implantation when compared with no treatment improves speech perception in noise (% correct responses: 43% vs. 15%, P , EBM Reviews - Health Technology Assessment , EBM Reviews - NHS Economic Evaluation Database , Embase , All Ovid MEDLINE(R) Search strategy: -------------------------------------------------------------------------------- 1 Hearing Loss, Unilateral/ (1078) 2 ((single side* or one

2020 Health Quality Ontario

176. Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis

of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de Internet: www.iqwig.de Extract of final report A16-70 Version 1.0 Biologics for rheumatoid arthritis 23 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - This report was prepared in collaboration with external experts. The responsibility for the contents of the report lies solely with IQWiG (...) is not relevant for the comparative benefit assessment of the biologics, since only 1 biologic (etanercept) is approved as first-line treatment without combination with MTX. b: Rituximab is approved in patients with inadequate response or intolerance to other DMARDs including 1 or more treatments with TNF inhibitors. ? Approved in the line of treatment (as of 28 June 2017). - Not approved in the line of treatment (as of 28 June 2017.) DMARD: disease-modifying antirheumatic drug; MTX: methotrexate; TNF: tumour

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

177. Benralizumab (asthma) - Benefit assessment according to §35a Social Code Book V

contribution to the dossier assessment. However, the advisor was not involved in the actual preparation of the dossier assessment. The responsibility for the contents of the dossier assessment lies solely with IQWiG. IQWiG employees involved in the dossier assessment: ? Sascha Abbas ? Michaela Florina Kerekes ? Inga Overesch ? Regine Potthast ? Min Ripoll ? Anke Schulz ? Corinna ten Thoren ? Volker Vervölgyi Keywords: benralizumab, asthma, benefit assessment Extract of dossier assessment A18-11 Version1.0 (...) of inadequate treatment of severe asthma does not comply with an ACT in severe refractory eosinophilic asthma if the option for treatment escalation is still available. The therapeutic indication also comprises patients for whom there is no further escalation option for their ongoing treatment, however. c: OCS should only be used on a short-term basis and in their lowest effective dose. It should be ensured in the OCS treatment of asthma that the OCS dosage does not permanently exceed the Cushing threshold

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

178. Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance Full Text available with Trip Pro

because they would not have been included in the original report. Schondorf R. Low P.A. Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia?. Neurology. 1993; 43 : 132-137 However, this group with comorbid conditions comprise a significant population in our clinics diagnosed with POTS. It is likely that the natural history, prognosis, and response to treatment are different between this “pure” group and that with the comorbid conditions, and therefore (...) , but there is a clear secondary and underlying cause for the excessive orthostatic tachycardia that should be addressed ( ), and that precludes the diagnosis of POTS. Table 5 Underlying conditions associated with PTOC • Acute hypovolemia (dehydration or blood loss) • Endocrinopathy (carcinoid, adrenal insufficiency, Cushing syndrome, hyperthyroidism, pheochromocytoma, etc) • Anemia • Anxiety and panic attacks • Medication side effects • Recreational drugs effects • Prolonged or sustained bed rest PTOC, postural

2020 Canadian Cardiovascular Society

179. Mepolizumab (asthma) - Benefit assessment according to §35a Social Code Book V

in adolescents and children aged 6 years and older) 20 December 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - Medical and scientific advice: ? Thomas O. F. Wagner, University Hospital Frankfurt, Frankfurt am Main, Germany IQWiG thanks the medical and scientific advisor for his contribution to the dossier assessment. However, the advisor was not involved in the actual preparation of the dossier assessment. The responsibility for the contents of the dossier assessment lies solely (...) available. However, the therapeutic indication also includes patients for whom there is no further escalation option for their current treatment. d: Only in patients who completely fulfil the criteria of the approval and of the note on treatment for omalizumab. e: Oral corticosteroids (OCS) should be used only on a short-term basis and in their lowest effective dose. In the OCS treatment of asthma, it should be ensured that the OCS dosage does not permanently exceed the Cushing threshold, if possible

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

180. Bariatric surgery in Belgium: organisation and payment of care before and after surgery

from a consensus or a voting process between the validators. The validators did not co-author the scientific report and did not necessarily all three agree with its content. • Finally, this report has been approved by common assent by the Executive Board. • Only the KCE is responsible for errors or omissions that could persist. The policy recommendations are also under the full responsibility of the KCE. Publication date: 29 June 2020 Domain: Health Services Research (HSR) MeSH: Bariatric surgery

2020 Belgian Health Care Knowledge Centre

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>